Eg5 Inhibitors -Pipeline Insights, 2016

Description: SUMMARY
The report, “Eg5 Inhibitors-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the Eg5 Inhibitors. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. The report Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Eg5 Inhibitors. The report Report also assesses the Eg5 Inhibitors therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Eg5 Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Eg5 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Eg5 Inhibitors and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete MOA intelligence and complete understanding over therapeutics development for Eg5 Inhibitors
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Eg5 Inhibitors pipeline depth and focus of indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidencebased Decisions

Contents:
- Eg5 Inhibitors Overview
- Eg5 Inhibitors Disease Associated
- Eg5 Inhibitors Pipeline Therapeutics
- Eg5 Inhibitors Therapeutics under Development by Companies
- Eg5 Inhibitors Filed and Phase III Products
- Comparative Analysis
- Eg5 Inhibitors Phase II Products
- Comparative Analysis
- Eg5 Inhibitors Phase I and IND Filed Products
- Comparative Analysis
- Eg5 Inhibitors Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Eg5 Inhibitors – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Eg5 Inhibitors – Discontinued Products
- Eg5 Inhibitors – Dormant Products
- Companies Involved in Therapeutics Development for Eg5 Inhibitors
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables
- Number of Products under Development for Eg5 Inhibitors by Therapy Area, 2016
- Number of Products under Development for Eg5 Inhibitors, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Eg5 Inhibitors Assessment by Monotherapy Products
- Eg5 Inhibitors Assessment by Combination Products
- Eg5 Inhibitors Assessment by Route of Administration
- Eg5 Inhibitors Assessment by Stage and Route of Administration
- Eg5 Inhibitors Assessment by Molecule Type
- Eg5 Inhibitors Assessment by Stage and Molecule Type
- Eg5 Inhibitors Therapeutics – Discontinued Products
- Eg5 Inhibitors Therapeutics – Dormant Products
- Products under Development by Companies, 2016

List of Figures
- Number of Products under Development for Eg5 Inhibitors by Therapy Area, 2016
- Number of Products under Development for Eg5 Inhibitors, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Eg5 Inhibitors Assessment by Monotherapy Products
- Eg5 Inhibitors Assessment by Combination Products
- Eg5 Inhibitors Assessment by Route of Administration
- Eg5 Inhibitors Assessment by Stage and Route of Administration
- Eg5 Inhibitors Assessment by Molecule Type
- Eg5 Inhibitors Assessment by Stage and Molecule Type

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3534693/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Eg5 Inhibitors -Pipeline Insights, 2016
Web Address: http://www.researchandmarkets.com/reports/3534693/
Office Code: SCD2STT

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 1250</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 4000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  
Mr  
Mrs  
Dr  
Miss  
Ms  
Prof  

First Name: ___________________________  Last Name: ___________________________

Email Address: * ___________________________

Job Title: ___________________________

Organisation: ___________________________

Address: ___________________________

City: ___________________________

Postal / Zip Code: ___________________________

Country: ___________________________

Phone Number: ___________________________

Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp